These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 5000470)

  • 41. Role of cellwall vaccine in prophylaxis of tuberculosis.
    Pal DP; Shriniwas
    Indian J Med Res; 1977 Mar; 65(3):340-5. PubMed ID: 411743
    [No Abstract]   [Full Text] [Related]  

  • 42. Differential Mycobacterium bovis BCG vaccine-derived efficacy in C3Heb/FeJ and C3H/HeOuJ mice exposed to a clinical strain of Mycobacterium tuberculosis.
    Henao-Tamayo M; Obregón-Henao A; Creissen E; Shanley C; Orme I; Ordway DJ
    Clin Vaccine Immunol; 2015 Jan; 22(1):91-8. PubMed ID: 25392011
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the protective efficacy of bacille calmette-Guérin vaccination against aerosol challenge with Mycobacterium tuberculosis and Mycobacterium bovis.
    Williams A; Davies A; Marsh PD; Chambers MA; Hewinson RG
    Clin Infect Dis; 2000 Jun; 30 Suppl 3():S299-301. PubMed ID: 10875804
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of immunogenicity and protective efficacy against Mycobacterium tuberculosis infection elicited by recombinant Mycobacterium bovis BCG expressing human Interleukin-12p70 and Early Secretory Antigen Target-6 fusion protein.
    Deng Y; Bao L; Yang X
    Microbiol Immunol; 2011 Nov; 55(11):798-808. PubMed ID: 21831202
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunotherapy of guinea pig cancer with BCG.
    Zbar B
    Johns Hopkins Med J Suppl; 1974; 3():121-30. PubMed ID: 4608693
    [No Abstract]   [Full Text] [Related]  

  • 46. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recombinant Mycobacterium bovis BCG.
    Bastos RG; Borsuk S; Seixas FK; Dellagostin OA
    Vaccine; 2009 Nov; 27(47):6495-503. PubMed ID: 19720367
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enhancement of antimycobacterial Th1-cell responses by a Mycobacterium bovis BCG prime-protein boost vaccination strategy.
    Lu M; Xia ZY; Bao L
    Cell Immunol; 2013; 285(1-2):111-7. PubMed ID: 24177251
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of systemic administration of BCG cell walls on bronchogenic carcinoma in hamsters.
    Zwilling BS; Springer ST; Kaufman DG
    J Natl Cancer Inst; 1977 May; 58(5):1473-7. PubMed ID: 323508
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adjuvanticity of mycobacterial cell walls.
    Azuma I; Kishimoto S; Yamamura Y; Petit JF
    Jpn J Microbiol; 1971 Mar; 15(2):193-7. PubMed ID: 4930810
    [No Abstract]   [Full Text] [Related]  

  • 51. [The protective activity of mycobacterial antigens. 3. Protective activity of killed mycobacterial bodies].
    Stavri D; Anagnoste V; Drăghici D
    Arch Roum Pathol Exp Microbiol; 1970; 29(1):91-101. PubMed ID: 4936247
    [No Abstract]   [Full Text] [Related]  

  • 52. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guérin (BCG) in infected mice.
    Kohama H; Umemura M; Okamoto Y; Yahagi A; Goga H; Harakuni T; Matsuzaki G; Arakawa T
    Vaccine; 2008 Feb; 26(7):924-32. PubMed ID: 18192091
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mycobacterium bovis BCG vaccination modulates TNF-alpha production after pulmonary challenge with virulent Mycobacterium tuberculosis in guinea pigs.
    Yamamoto T; Lasco TM; Uchida K; Goto Y; Jeevan A; McFarland C; Ly L; Yamamoto S; McMurray DN
    Tuberculosis (Edinb); 2007 Mar; 87(2):155-65. PubMed ID: 17289434
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: Protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations.
    Sharpe S; White A; Sarfas C; Sibley L; Gleeson F; McIntyre A; Basaraba R; Clark S; Hall G; Rayner E; Williams A; Marsh PD; Dennis M
    Tuberculosis (Edinb); 2016 Dec; 101():174-190. PubMed ID: 27865390
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunization of mice after airborne infection with various strains of BCG.
    Lefford MJ
    Am Rev Respir Dis; 1978 Jan; 117(1):103-9. PubMed ID: 339795
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Protection against bovine tuberculosis induced by oral vaccination of cattle with Mycobacterium bovis BCG is not enhanced by co-administration of mycobacterial protein vaccines.
    Wedlock DN; Aldwell FE; Vordermeier HM; Hewinson RG; Buddle BM
    Vet Immunol Immunopathol; 2011 Dec; 144(3-4):220-7. PubMed ID: 22005585
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plaque-forming cells in the spleens of rabbits immunized with viable BCG bacilli or oil cell wall vaccine from Mycobacterium bovis.
    Larson C; Baker MB; Smith D
    Am Rev Respir Dis; 1968 Apr; 97(4):715-8. PubMed ID: 4868647
    [No Abstract]   [Full Text] [Related]  

  • 58. The pathology of Mycobacterium tuberculosis infection.
    Sakamoto K
    Vet Pathol; 2012 May; 49(3):423-39. PubMed ID: 22262351
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Impact of Genome Region of Difference 4 (RD4) on Mycobacterial Virulence and BCG Efficacy.
    Ru H; Liu X; Lin C; Yang J; Chen F; Sun R; Zhang L; Liu J
    Front Cell Infect Microbiol; 2017; 7():239. PubMed ID: 28642843
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Heat-Shock Protein gp96 Enhances T Cell Responses and Protective Potential to Bacillus Calmette-Guérin Vaccine.
    Ding Y; Zheng H; Feng C; Wang B; Liu C; Mi K; Cao H; Meng S
    Scand J Immunol; 2016 Oct; 84(4):222-8. PubMed ID: 27417661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.